



Biotech Daily

Wednesday June 20, 2018

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: USCOM UP 10%; REVA DOWN 11%**
- * **BOTANIX 'OVERSUBSCRIBED' PLACEMENT RAISES \$8m**
- * **MEDADVISOR APPOINTS PDX FOR US PHARMACY ENTRY**
- * **CANADA APPROVES RECREATIONAL MARIJUANA; MMJ**
- * **LIFESPOT: MARIJUANA FOR AUSTRALASIA AND NORTH AMERICA**
- * **RACE REQUESTS 'UK REGULATORY DEVELOPMENTS' TRADING HALT**
- * **RHINOMED REQUESTS 'PRODUCT PARTNER' TRADING HALT**
- * **AUSTRALIAN SUPER INCREASES TO 7% IN OSPREY**

MARKET REPORT

The Australian stock market climbed 1.16 percent on Wednesday June 20, 2018 with the ASX200 up 70.5 points to 6,172.6 points.

Thirteen of the Biotech Daily Top 40 stocks were up, 21 fell, five traded unchanged and one was untraded. All three Big Caps were up.

Uscom was the best, up 1.5 cents or 9.7 percent to 17 cents with 157,323 shares traded.

Imugene climbed 7.7 percent; LBT was up five percent; Immutep improved 3.45 percent; Actinogen, Cochlear, Cynata, Oncosil, Polynovo and Universal Biosensors rose more than two percent; CSL, Orthocell and Resmed were up more than one percent; with Bionomics, Mesoblast and Nanosonics up by less than one percent.

Reva led the falls, down 2.5 cents or 10.9 percent to 20.5 cents with 36,586 shares traded.

Airxpanders lost eight percent; Compumedics and Optiscan fell more than seven percent; Prescient was down 6.25 percent; Ellex retreated 5.65 percent; Dimerix, Factor Therapeutics and Medical Developments fell more than four percent; Benitec, Clinuvel and Osprey were down more than three percent; Admedus shed two percent; Impedimed, Pro Medicus, Telix and Volpara were down more than one percent; with Neuren, Opthea, Sirtex and Starpharma down by less than one percent.

[BOTANIX PHARMACEUTICALS](#)

Botanix says it has raised \$8 million in an “oversubscribed” placement at 11 cents a share, an 8.3 percent discount to the previous closing price of 12 cents.

Botanix said that the funds would be used to accelerate the development of its synthetic cannabidiol BTX1204 for eczema and progress other pipeline products.

The company said the placement was to professional, institutional and sophisticated investors across Australia and Asia, including existing shareholders.

Botanix executive director Matt Callahan said the company was “in a strong position with two fully funded phase II-ready programs moving into the clinic, multiple pipeline products progressing into phase Ib patient studies in the near term and a novel technology platform”.

The company said that Argonaut Securities Pty Ltd and Bell Potter Securities were the joint lead managers to the placement with Vesparum Capital an independent capital markets advisor.

Botanix fell half a cent or 4.2 percent to 11.5 cents with 8.1 million shares traded.

[MEDADVISOR](#)

Medadvisor says it has a marketing and licence agreement with the Fort Worth, Texas-based PDX Inc to provide the Medadvisor prescription application at US pharmacies.

Medadvisor said PDX was a pharmacy dispensing software company that served more than 10,000 shops in the US and would be part of the first step in the commercialization of its use in the US, a process expected to be completed this year.

Medadvisor chief executive officer Robert Read said the agreement was the “first step on the path towards commercialization in the US”.

“Our product has received fantastic feedback from pharmacy chains throughout the region and to get our product into their stores it is important that it is connected to the key dispensing systems in the US,” Mr Read said.

“Dispensing systems are the backbone that enable pharmacies to order and receive medications for their patients and integration with a market leading dispensing software in the US provides us with the first piece of the puzzle to securing a position in the US market,” Mr Read said.

Medadvisor was up 0.7 cents or 17.5 percent to 4.7 cents with 5.2 million shares traded.

[GOVERNMENT OF CANADA, MMJ PHYTOTECH](#)

Canada’s Senate has passed Bill C-45, approving the recreational use of marijuana in Canada.

A spokesperson for Canada’s Minister of Health Ginette Petitpas Taylor told Biotech Daily that Bill C-45 ‘An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts (Cannabis Act)’ had passed the Senate. According to Canadian Parliamentary procedure, the Bill requires Royal Assent by Canada’s Governor General to become an Act of Parliament, which was expected in the coming days.

MMJ said it welcomed the Canadian Senate approval of the Bill and said it was “significant progress”.

MMJ chief executive officer Jason Conroy said the company was “very pleased that the Federal legalization of recreational cannabis in Canada is imminent and our portfolio is well-positioned to participate in that large market opportunity”.

MMJ was up 3.5 cents or 10.6 percent to 36.5 cents with 2.2 million shares traded.

LIFESPOT HEALTH

Lifespot says it is in discussions with North American and Australasian marijuana companies to finance the production of medicinal and recreational marijuana products. Lifespot said the pending legalization of recreational marijuana in Canada, the growing marijuana sales in the US and potential legislation changes in Australasia was a “huge first-mover advantage”.

The company said it would attend the International Cannabis Business Convention in Vancouver, British Columbia on June 24 and 25, 2018, to seek partnerships with North American companies and multinational pharmaceuticals, as well as advertising its Seng-vital marijuana vaporizer.

Lifespot was up 1.5 cents or 13.6 percent to 12.5 cents.

RACE ONCOLOGY

Race has requested a trading halt “pending an announcement in relation to regulatory developments in the UK”.

Trading will resume on June 22, 2018 or on an earlier announcement.

Race last traded at 24 cents.

RHINOMED

Rhinomed has requested a trading halt pending the execution of a non-binding terms sheet pertaining to potential joint development of [its] products”.

Trading will resume on June 22, 2018 or on an earlier announcement.

Rhinomed last traded up half a cent or 4.2 percent to 12.5 cents.

OSPREY MEDICAL

The Melbourne-based Australian Super Pty Ltd says it has increased its substantial shareholding in Osprey from 13,392,857 shares (5.20%) to 23,644,059 shares (6.96%). Australian Super said it bought the 10,251,202 shares on September 4, 2017 for 40 cents a share, when Osprey raised \$32.5 million in a placement and rights issue at 40 cents a share (BD: Aug 4, 30, 2017).

Last year, Brandon Capital said it had increased its holding in Osprey from 60,505,552 shares (23.8%) to 91,413,524 shares (26.9%) with the shares acquired in the .5 million placement and rights issue and held by Brandon Capital, the Medical Research and Commercialization Fund Pty Ltd for the MRCF Trust, BBF1 Trustco Pty Ltd for the Brandon Biosciences Fund No 1 Trust, BBF1 IIF Partnership LP, Australian Super Pty Ltd for Australian Super, and three MRCF Services entities (BD: Sep 6, 2018).

Osprey fell half a cent or 3.3 percent to 14.5 cents.